AMSTERDAM, The Netherlands, January 31, 2011 - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Union (EU) has finalized a EUR 3.3 million grant to the AIPGENE consortium, of which AMT is a member, for the development of a gene therapy product for Acute Intermittent Porphyria (AIP). AIP is a severe and progressive disease caused by the inability of the body to produce the heme protein, a component of hemoglobin, as well as other important proteins.

A Unique Store Concept Right Next to the City's Most Famous Running Spot